Last reviewed · How we verify
Non-antipsychotic medication
At a glance
| Generic name | Non-antipsychotic medication |
|---|---|
| Also known as | Antidepressants, Benzodiazepines |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Cue-based Intervention in Prospective Memory and Medication Adherence. (NA)
- Psychiatric Multi-omics and Neuroimaging Project
- Cognitive Impairment Characteristics and Biological Mechanisms in Untreated Severe Mental Illness
- Pharmacist-led Interventions in Psychiatric Patients (NA)
- An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (PHASE4)
- Caplyta in Borderline Personality Disorder (PHASE2)
- Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease
- CLOZAPINE Response in Biotype-1 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non-antipsychotic medication CI brief — competitive landscape report
- Non-antipsychotic medication updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI